Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
CSBR Stock Forecast 2025-2026
$6.04
Current Price
$83.28M
Market Cap
Buy 1
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to CSBR Price Targets
+98.7%
To High Target of $12.00
+98.7%
To Median Target of $12.00
+98.7%
To Low Target of $12.00
CSBR Price Momentum
-7.6%
1 Week Change
-10.4%
1 Month Change
+31.0%
1 Year Change
-29.5%
Year-to-Date Change
-49.6%
From 52W High of $11.99
+45.2%
From 52W Low of $4.16
📊 TOP ANALYST CALLS
Did CSBR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Champions Oncology is one of their latest high-conviction picks.
Latest CSBR Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, CSBR has a bullish consensus with a median price target of $12.00 (ranging from $12.00 to $12.00). The overall analyst rating is N/A (N/A/10). Currently trading at $6.04, the median forecast implies a 98.7% upside. This outlook is supported by 1 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Matt Hewitt at Craig-Hallum, projecting a 98.7% upside. Conversely, the most conservative target is provided by Matt Hewitt at Craig-Hallum, suggesting a 98.7% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CSBR Analyst Ratings
1
Buy
0
Hold
0
Sell
CSBR Price Target Range
Low
$12.00
Average
$12.00
High
$12.00
Current: $6.04
Latest CSBR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CSBR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2025 | Craig-Hallum | Matt Hewitt | Buy | Maintains | $12.00 |
| Dec 12, 2024 | Craig-Hallum | Matt Hewitt | Buy | Maintains | $8.00 |
| Sep 12, 2024 | Craig-Hallum | Matt Hewitt | Buy | Upgrade | $6.00 |
| Mar 13, 2024 | Craig-Hallum | Matt Hewitt | Hold | Downgrade | $N/A |
| Sep 22, 2023 | Roth MKM | Scott Henry | Buy | Maintains | $7.50 |
| Mar 15, 2021 | Roth Capital | Buy | Maintains | $16.00 | |
| Nov 18, 2019 | Benchmark | Speculative Buy | Initiates | $N/A | |
| Sep 20, 2019 | Roth Capital | Buy | Initiates | $N/A | |
| Jul 24, 2019 | Janney Montgomery Scott | Neutral | Downgrade | $N/A | |
| Jul 24, 2019 | Janney Capital | Neutral | Downgrade | $N/A | |
| Jul 17, 2018 | Craig-Hallum | Buy | Initiates | $N/A | |
| May 15, 2018 | Dawson James | Buy | Initiates | $N/A |
Champions Oncology, Inc. (CSBR) Competitors
The following stocks are similar to Champions Oncology based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
CSBR
Champions Oncology
mkt cap
83.28M
Champions Oncology, Inc. (CSBR) Financial Data
Champions Oncology, Inc. has a market capitalization of $83.28M with a P/E ratio of 28.8x. The company generates $56.88M in trailing twelve-month revenue with a 5.2% profit margin.
Revenue growth is -0.5% quarter-over-quarter, while maintaining an operating margin of -3.6% and return on equity of +182.3%.
Valuation Metrics
Market Cap
$83.28M
Enterprise Value
$78.92M
P/E Ratio
28.8x
PEG Ratio
-0.2x
Price/Sales
1.5x
Growth & Margins
Revenue Growth (YoY)
-0.5%
Gross Margin
+42.9%
Operating Margin
-3.6%
Net Margin
+5.2%
EPS Growth
-0.5%
Financial Health
Cash/Price Ratio
+12.4%
Current Ratio
0.9x
Debt/Equity
167.7x
ROE
+182.3%
ROA
+6.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Champions Oncology, Inc. (CSBR) Business Model
About Champions Oncology, Inc.
What They Do
Develops technologies for oncology drug discovery.
Business Model
Champions Oncology generates revenue by providing personalized solutions and predictive insights to pharmaceutical companies and research institutions. Their primary offering, TumorGraft Technology, allows for the testing of cancer therapies on patient-derived tumor cells, facilitating a better understanding of treatment responses and accelerating drug development.
Additional Information
The company's services are essential for advancing precision medicine and optimizing clinical trial designs, positioning Champions Oncology as a valuable partner in global cancer research initiatives.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
213
CEO
Mr. Robert Brainin
Country
United States
IPO Year
2007
Website
www.championsoncology.comChampions Oncology, Inc. (CSBR) Latest News & Analysis
Latest News
Quick Summary
Champions Oncology (NASDAQ: CSBR) held its Q1 2026 earnings call on September 15, 2025, featuring CEO Robert Brainin and CFO David Miller.
Why It Matters
Champions Oncology's Q1 earnings call signals financial performance insights and strategic direction, critical for assessing growth potential and investment viability.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Champions Oncology, Inc. reported steady revenue and data growth for Q1 FY 2026, ending July 31, 2025, alongside a leadership change.
Why It Matters
Champions Oncology's steady revenue and data growth indicate strong performance, while new leadership may drive future innovation, positively influencing investor sentiment and stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Champions Oncology, Inc. reported Q1 FY 2026 revenue of $14 million and an adjusted EBITDA of $60,000. Rob Brainin has been appointed as CEO to drive growth.
Why It Matters
Champions Oncology's steady revenue and new CEO signal potential growth, indicating a positive outlook that could attract investor interest and influence stock performance.
Source: Accesswire
Market Sentiment:
Neutral
Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025
2 months ago
Quick Summary
Champions Oncology, Inc. (Nasdaq:CSBR) will report Q1 results on September 15, 2025, after market close, followed by a conference call at 4:30 PM the same day.
Why It Matters
Champions Oncology's upcoming financial results and conference call could significantly impact its stock price, reflecting its performance and future outlook in the oncology market.
Source: Accesswire
Market Sentiment:
Neutral
Quick Summary
Champions Oncology (NASDAQ: CSBR) will hold its Q4 2025 earnings call on July 23, 2025, at 4:30 PM ET, featuring CEO Ronnie Morris and CFO David Barry Miller.
Why It Matters
Champions Oncology's Q4 earnings call provides insights into financial performance and future outlook, crucial for assessing investment potential and market confidence in the company.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Champions Oncology reported a 14% revenue growth for FY 2025, reaching $57M. Q4 revenue was $12.3M with a net income of $4.6M. The company maintains a cash balance of $9.8M.
Why It Matters
Champions Oncology's 14% revenue growth and return to profitability signal strong business momentum and potential long-term value, attracting investor interest and confidence in future performance.
Source: Accesswire
Market Sentiment:
Neutral
Frequently Asked Questions About CSBR Stock
What is Champions Oncology, Inc.'s (CSBR) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Champions Oncology, Inc. (CSBR) has a median price target of $12.00. The highest price target is $12.00 and the lowest is $12.00.
Is CSBR stock a good investment in 2026?
According to current analyst ratings, CSBR has 1 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $6.04. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for CSBR stock?
Wall Street analysts predict CSBR stock could reach $12.00 in the next 12 months. This represents a 98.7% increase from the current price of $6.04. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Champions Oncology, Inc.'s business model?
Champions Oncology generates revenue by providing personalized solutions and predictive insights to pharmaceutical companies and research institutions. Their primary offering, TumorGraft Technology, allows for the testing of cancer therapies on patient-derived tumor cells, facilitating a better understanding of treatment responses and accelerating drug development.
What is the highest forecasted price for CSBR Champions Oncology, Inc.?
The highest price target for CSBR is $12.00 from Matt Hewitt at Craig-Hallum, which represents a 98.7% increase from the current price of $6.04.
What is the lowest forecasted price for CSBR Champions Oncology, Inc.?
The lowest price target for CSBR is $12.00 from Matt Hewitt at Craig-Hallum, which represents a 98.7% increase from the current price of $6.04.
What is the overall CSBR consensus from analysts for Champions Oncology, Inc.?
The overall analyst consensus for CSBR is bullish. Out of 3 Wall Street analysts, 1 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $12.00.
How accurate are CSBR stock price projections?
Stock price projections, including those for Champions Oncology, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 3:16 PM UTC